David Bhatt

David Bhatt has contributed to standardizing tumor-infiltrating lymphocyte assessment as a prognostic and predictive biomarker in breast cancer and other solid tumors, developing consensus scoring guidelines adopted by international pathology working groups. His research has examined the clinical significance of TIL levels in triple-negative breast cancer, where high TIL tumors show favorable prognosis and enhanced response to checkpoint immunotherapy and standard chemotherapy. He has characterized the prognostic value of TILs across breast cancer subtypes including HER2-positive and HR+ disease, and their predictive utility for benefit from immunotherapy combination strategies. His work on standardized TIL scoring methodology and its analytical validation across pathology laboratories has contributed to making TIL assessment reproducible and clinically actionable as a routine biomarker.